• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于提高利培酮生物利用度和疗效的先进药物递送技术

Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone.

作者信息

Rathi Ritu, Mehetre Nitin Martandrao, Goyal Shuchi, Singh Inderbir, Huanbutta Kampanart, Sangnim Tanikan

机构信息

Chitkara College of Pharmacy, Chitkara University, Patiala, PB, India.

Department of Manufacturing Pharmacy, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.

出版信息

Int J Nanomedicine. 2024 Nov 30;19:12871-12887. doi: 10.2147/IJN.S492684. eCollection 2024.

DOI:10.2147/IJN.S492684
PMID:39640049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11618854/
Abstract

Multidisciplinary research has been conducted on novel drug delivery technologies to maximize therapeutic advantages while curtailing undesirable reactions. Drugs under BCS Class II often have a low bioavailability because the dissolution phase limits the absorption efficiency. In this review, risperidone was used as a pharmacological model to examine the impact of solubility enhancement at the primary administration site for such pharmaceuticals. For tackling drug-related pertains like disease diagnostics, therapy, and prophylactic measures at the cellular or molecular levels, implementing nanocarriers in therapeutics has significant potential. The comprehensive pharmaceutical compositions of risperidone nano-microparticles that have been developed to alleviate psychosis are highlighted in the study, which also illustrates potential future developments in such domains.

摘要

针对新型药物递送技术开展了多学科研究，以在减少不良反应的同时最大化治疗优势。BCS II类药物通常生物利用度较低，因为溶出阶段限制了吸收效率。在本综述中，利培酮被用作药理学模型，以研究在这类药物的主要给药部位提高溶解度的影响。为了在细胞或分子水平上解决与疾病诊断、治疗和预防措施等药物相关问题，在治疗中应用纳米载体具有巨大潜力。该研究重点介绍了为缓解精神病而研发的利培酮纳米微粒的综合药物组合物，还阐述了该领域未来的潜在发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/aab464c6978a/IJN-19-12871-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/1f1d77f15cf3/IJN-19-12871-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/f46a4f89601f/IJN-19-12871-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/18a7e1366274/IJN-19-12871-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/b3f3235029bf/IJN-19-12871-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/aab464c6978a/IJN-19-12871-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/1f1d77f15cf3/IJN-19-12871-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/f46a4f89601f/IJN-19-12871-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/18a7e1366274/IJN-19-12871-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/b3f3235029bf/IJN-19-12871-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ae/11618854/aab464c6978a/IJN-19-12871-g0005.jpg

相似文献

1
Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone.用于提高利培酮生物利用度和疗效的先进药物递送技术
Int J Nanomedicine. 2024 Nov 30;19:12871-12887. doi: 10.2147/IJN.S492684. eCollection 2024.
2
Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances.利培酮的肠胃外纳米乳剂增强急性精神病中的脑递送：理化性质和体内性能。
Int J Pharm. 2017 Nov 30;533(2):421-430. doi: 10.1016/j.ijpharm.2017.05.051. Epub 2017 May 25.
3
Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.用于鼻脑递送的神经活性药物负载壳聚糖纳米颗粒的制备与评价：体外表征及体内行为研究
Curr Drug Deliv. 2019;16(2):123-135. doi: 10.2174/1567201815666181011121750.
4
Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics.将控释口服给药应用于一系列非典型抗精神病药物先导化合物的临床前可行性评估。
J Pharm Sci. 2006 Apr;95(4):883-95. doi: 10.1002/jps.20550.
5
Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion.利培酮口服固体自乳化脂质制剂的研发及其体外溶出和消化性能的改善
Eur J Pharm Biopharm. 2017 May;114:239-249. doi: 10.1016/j.ejpb.2017.01.015. Epub 2017 Jan 31.
6
Optimization and in vitro toxicity evaluation of G4 PAMAM dendrimer-risperidone complexes.G4 PAMAM 树状聚合物-利培酮配合物的优化及其体外毒性评价。
Eur J Med Chem. 2011 Mar;46(3):845-50. doi: 10.1016/j.ejmech.2010.12.021. Epub 2010 Dec 22.
7
Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique.采用液固技术研究在主要吸收部位溶解度增加对BCS II类药物（利培酮）生物利用度的影响。
Drug Deliv. 2017 Nov;24(1):328-338. doi: 10.1080/10717544.2016.1250140.
8
Phospholipid based self-nanoemulsifying self-nanosuspension (p-SNESNS) as a dual solubilization approach for development of formulation with diminished food effect: Fast/fed in vivo pharmacokinetics study in human.基于磷脂的自微乳自纳米混悬（p-SNESNS）作为一种双重增溶方法，用于开发减食物效应的制剂：人体快速/进食体内药代动力学研究。
Eur J Pharm Sci. 2017 Nov 15;109:244-252. doi: 10.1016/j.ejps.2017.08.017. Epub 2017 Aug 18.
9
Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.载利培酮固体脂质纳米粒的长期稳定性、生物相容性和口服递药潜能。
Int J Pharm. 2012 Oct 15;436(1-2):798-805. doi: 10.1016/j.ijpharm.2012.07.058. Epub 2012 Aug 4.
10
Preparation and characterization of nanoparticles containing an atypical antipsychotic agent.含非典型抗精神病药物纳米颗粒的制备与表征
Nanomedicine (Lond). 2007 Apr;2(2):233-40. doi: 10.2217/17435889.2.2.233.

引用本文的文献

1
Advancements in Nanotherapeutics for the Treatment of Depression via Intranasal Pathway: A Review.经鼻途径治疗抑郁症的纳米疗法进展：综述
Int J Nanomedicine. 2025 Jun 9;20:7323-7342. doi: 10.2147/IJN.S525759. eCollection 2025.

本文引用的文献

1
The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review.新型抗精神病药物鲁马哌酮（ITI-007）治疗精神分裂症的系统评价
Brain Sci. 2023 Nov 26;13(12):1641. doi: 10.3390/brainsci13121641.
2
Gas therapy strategies for depression and schizophrenia: A review.气体治疗策略在抑郁症和精神分裂症中的应用：综述。
Medicine (Baltimore). 2023 Nov 17;102(46):e36156. doi: 10.1097/MD.0000000000036156.
3
Anticancer potentials of metformin loaded coconut oil nanoemulsion on MCF-7, HepG2 and HCT-116 cell lines.
载二甲双胍的椰子油纳米乳的抗癌潜力对 MCF-7、HepG2 和 HCT-116 细胞系的影响。
Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):419-427. doi: 10.1080/21691401.2023.2246145.
4
Preparation of multivesicular liposomes for the loco-regional delivery of Vancomycin hydrochloride using active loading method: drug release and antimicrobial properties.采用主动载药法制备用于局部递送盐酸万古霉素的多囊泡脂质体：药物释放及抗菌特性
J Liposome Res. 2024 Mar;34(1):77-87. doi: 10.1080/08982104.2023.2220805. Epub 2023 Jun 7.
5
Formulation Strategies of Nanosuspensions for Various Administration Routes.用于不同给药途径的纳米混悬液的制剂策略
Pharmaceutics. 2023 May 17;15(5):1520. doi: 10.3390/pharmaceutics15051520.
6
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.乌洛托隆：TAAR1 激动剂治疗精神分裂症的初步疗效和安全性的综述。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1543-1556. doi: 10.1007/s00406-023-01580-3. Epub 2023 May 10.
7
The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia.男性精神分裂症患者的下丘脑-垂体-性腺轴。
Int J Mol Sci. 2023 Mar 30;24(7):6492. doi: 10.3390/ijms24076492.
8
Development and Evaluation of PLGA Nanoparticle-Loaded Organogel for the Transdermal Delivery of Risperidone.用于利培酮经皮给药的聚乳酸-羟基乙酸共聚物纳米颗粒负载有机凝胶的研制与评价
Gels. 2022 Nov 2;8(11):709. doi: 10.3390/gels8110709.
9
Influence of the filler distribution on PDMS-graphene based nanocomposites selected properties.填料分布对 PDMS-石墨烯基纳米复合材料选定性能的影响。
Sci Rep. 2022 Nov 9;12(1):19038. doi: 10.1038/s41598-022-23735-3.
10
Advancements in Rectal Drug Delivery Systems: Clinical Trials, and Patents Perspective.直肠给药系统的进展：临床试验及专利视角
Pharmaceutics. 2022 Oct 17;14(10):2210. doi: 10.3390/pharmaceutics14102210.